AROI-ESTRO GYN Teaching Course

Take home messages

 Elective lymph node target: 45-50Gy EBRT  Perspective of reducing morbidity with 45Gy  Pathological lymph nodes: 55-60Gy EBRT  Balance between tumour control and morbidity  Primary tumour (CTV HR ):  With more IC/IS BT it is possible to reduce EBRT dose to 45Gy  Overall treatment time: <50 days >85-90Gy EBRT+BT  Balance between EBRT and BT

19